middl
east
respiratori
syndrom
coronaviru
merscov
first
isol
patient
kingdom
saudi
arabia
june
approxim
incid
case
date
manag
middl
east
howev
diseas
export
countri
north
america
asia
europ
africa
major
solitari
case
caus
secondari
spread
june
korea
experienc
largest
outbreak
outsid
saudi
arabia
extend
chain
transmiss
involv
multipl
gener
case
includ
patient
death
demonstr
potenti
merscov
widespread
humantohuman
transmiss
lead
disrupt
health
socioeconom
system
anticoronaviru
therapi
challeng
develop
coronavirus
biolog
divers
rapidli
mutat
henc
effect
agent
one
strain
especi
target
replic
mechan
may
useless
anoth
strain
anim
studi
logist
technic
difficult
number
anim
model
avail
limit
found
design
biosafeti
level
challeng
result
identifi
lack
novel
effect
treatment
modal
pauciti
clinic
trial
current
treatment
option
mer
extrapol
outbreak
sever
acut
respiratori
syndrom
coronaviru
sarscov
influenza
outbreak
heterogen
rang
treatment
use
mer
patient
exampl
recent
involv
patient
saudi
arabia
receiv
broadspectrum
antibiot
receiv
hydrocortison
receiv
antivir
treatment
antivir
treatment
includ
mycophenol
mofetil
fundament
differ
sarscov
merscov
put
question
basi
appli
evid
treatment
former
latter
although
merscov
phylogenet
relat
sarscov
differ
biolog
makeup
pathogenesi
clinic
manifest
contrast
sarscov
bind
angiotensinconvert
enzym
receptor
merscov
bind
receptor
dipeptidyl
peptidas
merscov
vivo
target
wide
varieti
cell
includ
type
ii
alveolar
cell
noncili
epitheli
cell
clara
cell
endotheli
cell
ciliat
epitheli
cell
infect
merscov
unlik
sarscov
also
infect
replic
human
monocytederiv
increas
express
major
histocompat
complex
class
costimulatori
molecul
lead
exagger
activ
immun
respons
includ
express
chemokin
differ
receptor
usag
suscept
type
type
iii
interferon
may
account
differ
diseas
pattern
organ
tropism
viru
current
treatment
option
mer
categor
immunotherapi
virusspecif
antibodi
convalesc
plasma
polyclon
monoclon
antibodi
produc
vitro
genet
modifi
anim
antivir
agent
attempt
also
made
repurpos
approv
pharmaceut
drug
merscov
treatment
multipl
compound
includ
oestrogen
receptor
dopamin
receptor
antagonist
display
activ
vero
cell
model
consider
data
avail
welldesign
clinic
trial
yet
complet
low
case
number
one
site
known
difficulti
trial
outbreak
set
refer
public
review
identifi
search
pubm
us
cdc
websit
april
search
term
use
combin
treatment
middl
east
respiratori
syndrom
coronaviru
respiratori
ill
middl
east
respiratori
syndrom
coronaviru
addit
refer
list
articl
also
consid
type
studi
includ
vitro
vivo
clinic
studi
treatment
option
merscov
extrapol
sarscov
relev
articl
treatment
two
coronavirus
review
full
text
identifi
studi
retriev
articl
publish
foreign
languag
chines
one
author
nativ
speaker
total
articl
critic
assess
merscov
sarscov
featur
therapeut
includ
convalesc
plasma
immunoglobulin
monoclon
antibodi
ribavirin
proteas
inhibitor
interferon
corticosteroid
nitazoxanid
immunomodulatori
agent
includ
cyclosporin
chloroquin
mycophenol
acid
fusion
inhibitor
merscov
prophylact
therapeut
treatment
hightitr
mer
immun
camel
serum
abl
diminish
weight
loss
reduc
lung
histolog
chang
acceler
viru
clearanc
merscov
convalesc
plasma
sar
patient
shown
via
indirect
immunofluoresc
test
contain
crossreact
antibodi
includ
howev
neutral
crossreact
sarscov
merscov
demonstr
crossreact
sera
therefor
unlik
use
import
consider
mer
affect
countri
sar
survivor
china
canada
singapor
novel
merscovspecif
poli
monoclon
antibodi
mab
develop
rapidli
produc
immun
antibodi
human
phage
memori
b
cell
recov
transchromosom
cattl
success
gener
purifi
human
rapidli
decreas
viral
lung
titr
receptortransduc
mice
monoclon
antibodi
target
merscov
spike
glycoprotein
shown
strong
neutral
effect
vitro
anim
studi
protein
surfac
structur
protein
critic
viru
entri
host
cell
mous
model
transnas
mab
effect
prophylact
postexposur
set
viral
similarli
rhesu
model
mab
administr
result
reduc
lung
patholog
computedtomographi
howev
caveat
use
mab
potenti
viral
escap
resist
emerg
safeti
profil
vivo
effect
need
explor
two
case
report
use
intraven
immunoglobulin
ivig
treat
one
patient
saudi
arabia
given
ivig
togeth
highdos
corticosteroid
mer
case
import
usa
ivig
given
day
patient
recov
ivig
unlik
effect
due
expect
absenc
merscov
antibodi
usa
research
protocol
collect
test
convalesc
plasma
recov
mer
patient
formul
share
saudi
initi
feasibl
safeti
studi
may
protocol
promot
clinic
character
mer
patient
screen
recov
expos
individu
complet
expect
june
howev
studi
hamper
logist
challeng
local
technic
capac
donor
recent
commun
princip
investig
studi
reveal
antibodi
titr
convalesc
plasma
low
produc
therapeut
random
control
studi
rct
util
convalesc
plasma
sar
outbreak
one
retrospect
four
prospect
studi
sarsaffect
patient
undertaken
china
hong
kong
taiwan
demonstr
earlier
discharg
rapid
decreas
viraemia
surviv
promis
outcom
also
observ
delay
administr
median
day
pentaglobin
igmenrich
immunoglobulin
prepar
led
improv
clinic
paramet
radiolog
appear
sever
sar
patient
continu
deterior
despit
corticosteroid
ribavirin
similarli
subsequ
outbreak
prospect
cohort
studi
intens
care
patient
show
use
convalesc
plasma
abl
reduc
respiratori
tract
viral
load
serum
cytokin
respons
posit
effect
patient
confirm
multicentr
rct
use
hyperimmun
ivig
intens
care
earli
administr
within
day
symptom
onset
associ
lower
viral
load
reduc
mortal
systemat
review
metaanalysi
univers
nottingham
includ
studi
sarscov
infect
sever
influenza
conclud
statist
signific
reduct
mortal
convalesc
plasma
administ
earli
compar
placebo
howev
studi
deem
low
qualiti
heterogen
lack
control
group
effect
convalesc
plasma
ivig
could
discern
effect
patient
comorbid
stage
ill
treatment
possibl
theoret
drawback
convalesc
plasma
immunopotenti
infect
passiv
immun
effect
specif
limit
number
virus
includ
sever
hepat
report
immun
ferret
thought
mediat
antibodi
enhanc
sarscov
infect
howev
reproduc
monkey
model
sarscov
proteinspecif
igg
level
monkey
lung
tissu
found
increas
rechalleng
sar
cov
enhanc
viral
replic
immunopotenti
clinic
use
convalesc
plasma
immun
globulinrel
product
treatment
coronaviru
report
plasma
product
vari
region
depend
diseas
epidemiolog
may
contain
therapeut
level
antibodi
public
health
england
evalu
uk
ivig
show
merscov
neutral
saudi
arabia
seroposit
antimerscov
found
amongst
healthi
volunt
vari
provinc
age
exposur
camel
type
type
ii
type
iii
ifn
exhibit
activ
potent
compar
merscov
time
sensit
sarscov
vero
virus
caus
lysi
target
cell
effect
inhibit
ifn
uninfect
cell
ifn
highest
util
prophylaxi
earli
ifn
display
synergist
characterist
use
combin
vitro
studi
administ
togeth
inhibit
sarscov
plaqu
format
replic
combin
ribavirin
effect
reduc
merscov
replic
vero
combin
decreas
dose
ribavirin
requir
respect
biolog
plausibl
combin
studi
via
microarray
show
ribavirin
target
merscov
gene
involv
pathogen
recognit
cytokin
releas
immun
combin
found
effect
rhesu
common
model
ifn
ribavirin
andor
lopinavir
administ
treatment
led
reduc
viru
replic
moder
host
respons
improv
clinic
outcom
ifn
corticosteroid
studi
openlabel
uncontrol
studi
patient
diagnos
probabl
interferon
corticosteroid
arm
better
oxygen
satur
rapid
resolut
radiograph
lung
abnorm
lower
level
creatin
kinas
compar
corticosteroid
arm
howev
standard
regimen
use
advers
event
well
document
merscov
role
highlight
studi
compar
earli
immun
respons
two
first
patient
succumb
rapidli
found
significantli
lower
secret
serum
bronchoscopi
lavag
sampl
patient
surviv
infect
use
ribavirin
describ
four
case
five
retrospect
cohort
studi
involv
mainli
critic
ill
patient
requir
mechan
ventil
mortal
five
retrospect
studi
rang
higher
recogn
mortal
associ
mer
studi
method
heterogen
time
ifn
ribavirin
combin
treatment
administ
inconsist
describ
one
studi
investig
impact
earlier
administr
ifn
studi
involv
mechan
ventil
patient
twentytwo
given
ribavirin
median
time
therapi
administr
day
compar
receiv
ribavirin
treatment
group
improv
surviv
day
mortal
treatment
group
versu
compar
group
p
day
mortal
treatment
group
versu
compar
group
p
anoth
retrospect
studi
show
signific
differ
outcom
patient
given
combin
ribavirin
mortal
patient
receiv
compar
receiv
p
effect
mycophenol
acid
combin
therapi
studi
recent
retrospect
observ
studi
saudi
arabia
involv
although
univari
analysi
demonstr
improv
surviv
patient
treat
combin
multivari
analysi
consid
sever
ill
show
associ
treatment
surviv
ifn
wellestablish
agent
routin
avail
use
viral
hepat
malign
leukaemia
renal
cell
carcinoma
multipl
sclerosi
shorteract
prepar
prefer
rather
pegylatedifn
achiev
fast
onset
action
util
suggest
better
earli
infect
inhal
remain
investig
phase
trial
patient
lopinavir
found
inhibitori
merscov
vitro
vero
cell
mean
effect
concentr
screen
fdaapprov
drug
antimerscov
lopinavir
plasma
concentr
similar
observ
patient
atazanavir
ritonavir
found
inact
common
marmoset
model
lopinavirritonavir
effect
bring
improv
clinic
radiolog
patholog
find
lung
tissu
lower
mean
viral
load
lung
kidney
tissu
compar
untreat
observ
studi
patient
affect
sar
suggest
reduct
mortal
less
progress
acut
respiratori
distress
syndrom
ard
lopinavirritonavir
combin
patient
receiv
ribavirin
lopinavirritonavir
corticosteroid
lower
day
ard
mortal
receiv
ribavirin
howev
studi
determin
systemat
review
inconclus
due
select
treatment
two
case
report
show
posit
outcom
lopinavirritonavir
type
ifn
ribavirin
combin
therapi
greek
patient
clear
viraemia
day
initi
tripl
therapi
administ
day
ill
ribavirin
broad
spectrum
activ
viral
sarscov
four
six
vitro
studi
found
antivir
howev
virolog
effect
ribavarin
found
sarscov
anim
model
use
mous
model
even
show
ribavirin
may
prolong
enhanc
viral
replic
similarli
merscov
ribavirin
inhibitori
high
concentr
vero
cell
inhibitori
concentr
ribavirin
determin
howev
human
level
achiev
follow
high
mg
intraven
ribavirin
monotherapi
studi
anim
model
merscov
systemat
review
sar
treatment
studi
deem
inconclus
due
inconsist
report
outcom
inconsist
treatment
regimen
control
group
bias
control
group
effect
ribavirin
could
distinguish
effect
therapi
corticosteroid
singlecentr
rct
sar
patient
compar
ribavirin
show
signific
differ
day
symptom
improv
four
present
evid
possibl
harm
includ
haemolyt
anaemia
liver
dysfunct
metabol
synergi
ribavirin
ifn
discuss
section
ifn
although
mycophenol
acid
vitro
murin
effect
sarscov
inhibit
merscov
concentr
achiev
standard
clinic
oral
display
synergi
thiopurin
vitro
howev
common
marmoset
mycophenol
acidtr
anim
develop
sever
andor
fatal
diseas
higher
mean
viral
load
copiesglyceraldehyd
dehydrogenas
p
untreat
mortal
rate
h
postinocul
mer
cov
untreat
mycophenol
acidtr
versu
lopinavirritonavirtr
use
mycophenol
acid
monotherapi
report
mer
mycophenol
acid
combin
therapi
describ
retrospect
observ
studi
saudi
arabia
involv
patient
patient
receiv
mycophenol
acid
surviv
howev
group
patient
lower
acut
physiolog
chronic
health
evalu
ii
apacheii
score
compar
rest
receiv
varieti
antivir
agent
includ
ribavirin
steroid
antibiot
low
micromolar
noncytotox
concentr
cyclosporin
strongli
affect
replic
sarscov
merscov
vero
cell
cyclosporin
render
sarscov
rna
protein
synthesi
almost
undetect
suggest
earli
block
clinic
data
avail
efficaci
cyclosporin
sar
mer
cyclosporin
readili
avail
due
use
solidorgan
transplant
patient
therapi
autoimmun
condit
rheumatoid
arthriti
psoriasi
immun
suppress
effect
rais
concern
set
infect
especi
high
ratio
standard
therapeut
dosag
chloroquin
inhibitori
vitro
multipl
virus
includ
influenza
dengu
viru
merscov
concentr
achiev
standard
clinic
oral
howev
reduc
viral
replic
sarscov
infect
mice
possibl
cell
surfac
pathway
simultan
clinic
data
avail
efficaci
chloroquin
coronavirus
use
season
prophylaxi
influenza
studi
larg
chloroquin
well
toler
fail
prevent
diseas
nitazoxanid
possess
potent
antivir
activ
influenza
one
top
three
inhibitor
demonstr
robust
anticoronaviru
activ
recent
screen
nih
clinic
collect
shown
inhibit
mer
cov
cultur
cell
similar
level
observ
influenza
virus
achiev
human
follow
twice
daili
administr
nitazoxanid
extendedreleas
tablet
peak
trough
plasma
concentr
report
clinic
data
efficaci
nitazoxanid
sar
mer
two
phase
rct
show
benefit
childhood
respiratori
infect
uncompl
influenza
adult
teicoplanin
found
potent
prevent
entri
merscov
sarscov
pseudotyp
virus
host
cellular
cytoplasm
furthermor
teicoplanin
inhibitori
effect
replicationcompet
viruslik
particl
low
teicoplanin
clinic
effect
treatment
gramposit
bacteri
infect
includ
enterococcu
faecali
staphylococc
aureu
streptococcu
viridan
pharmacodynam
studi
specif
merscov
requir
discern
antivir
efficaci
analog
mechan
mab
antivir
peptid
target
variou
region
protein
prevent
merscov
entri
host
cell
camostat
serin
proteas
inhibitor
good
safeti
profil
use
treat
chronic
pancreat
human
suppress
merscov
entri
human
bronchial
submucos
glandderiv
cell
viru
growth
howev
found
efficaci
merscov
infect
deriv
cell
immatur
lung
tissu
anoth
type
fusion
inhibitor
vitro
studi
heptad
repeat
peptid
synthes
peptid
deriv
domain
merscov
protein
specif
bind
domain
viral
protein
block
merscov
replic
proteinmedi
intranas
administr
effect
protect
adenoviru
dipeptidyl
peptidas
mice
infect
merscov
strain
without
mutat
region
protein
reduct
viral
titr
lung
protect
enhanc
combin
combin
antivir
peptid
target
differ
region
subunit
protein
theoret
may
overcom
risk
drug
resist
investig
fusion
inhibitor
mer
remain
preclin
clinic
data
efficaci
fusion
inhibitor
sar
mer
mannosebind
lectin
mbl
key
molecul
innat
immun
function
anteantibodi
specif
antibodi
respons
mbl
inhibit
viral
bind
via
sarscov
retrospect
studi
serum
sar
patient
control
subject
show
higher
frequenc
haplotyp
associ
low
defici
level
mbl
sar
patient
control
mbl
defici
therefor
possibl
suscept
factor
acquisit
sar
mbl
remain
investig
therapi
clinic
data
efficaci
mbl
sar
mer
corticosteroid
wide
use
sar
due
antiinflammatori
cohort
treat
simultan
ribavirin
howev
potenti
local
system
immunosuppress
corticosteroid
one
rct
conclud
administr
corticosteroid
might
enhanc
viral
replic
lung
shown
higher
plasma
sarscov
viral
load
slower
serum
viral
clearanc
week
ill
patient
given
hydrocortison
given
normal
salin
n
earli
phase
similar
find
corticosteroid
test
influenzaaffect
retrospect
cohort
studi
show
use
corticosteroid
associ
increas
risk
prolong
lower
respiratori
tract
viral
replic
nosocomi
infect
ventilatorassoci
pneumonia
higher
mani
patient
sever
mer
treat
system
highdos
corticosteroid
intend
revers
progress
respiratori
distress
prevent
lung
fibrosi
proven
corticosteroid
improv
longerterm
outcom
ard
routin
use
addit
corticosteroid
also
associ
osteonecrosi
delirium
challeng
select
appropri
pharmacolog
treatment
face
novel
infect
inconclus
data
drawn
mani
sourc
despit
discov
fairli
larg
number
repurpos
drug
activ
merscov
fulfil
potenti
clinic
set
agent
drawback
either
high
ratio
clinic
dosag
immunosuppress
side
effect
discourag
clinic
trial
sporad
epidemiolog
also
made
patient
recruit
clinic
trial
difficult
use
therapeut
merscov
remain
investig
data
extrapol
use
sar
either
vitro
clinic
best
specul
valu
convalesc
plasma
ifn
without
ribavirin
lopinavirritonavir
like
benefici
evalu
retrospect
nonrandom
intervent
data
obtain
sar
outbreak
show
convalesc
plasma
brought
rapid
decreas
viraemia
reduc
treatment
convalesc
plasma
like
effect
signific
viraemia
henc
earli
administr
prospect
human
studi
investig
use
convalesc
plasma
mer
ongo
face
logist
recruit
challeng
plasma
product
immunoglobulin
vari
geograph
likewis
vari
efficaci
given
small
number
mer
patient
signific
mortal
infect
may
suffici
convalesc
sera
scalabl
option
particularli
outsid
middl
east
crossreact
sarscov
merscov
antibodi
observ
unlik
use
mab
could
offer
use
altern
rapidli
reproduc
far
shown
high
potenc
specif
howev
develop
like
temper
challeng
licens
fullscal
product
afford
cost
undefin
popul
ifn
ribavirin
without
lopinavirritonavir
report
therapi
mer
although
nonhuman
primat
studi
show
combin
treatment
ifn
ribavirin
andor
lopinavir
result
reduc
viru
replic
moder
host
respons
improv
clinic
five
smallscal
retrospect
studi
critic
ill
patient
fail
show
mortal
discrep
vitro
vivo
find
may
relat
high
ratio
drug
delay
drug
earli
drug
administr
essenti
mer
patient
rapid
progress
death
sar
ribavirin
use
caution
vitro
studi
merscov
requir
high
serum
concentr
dose
ribavirin
reduc
use
togeth
associ
multipl
side
effect
includ
haemolysi
electrolyt
imbal
liver
impair
occur
treat
lopinavir
shown
limit
observ
studi
result
lower
mortal
less
progress
ard
use
report
one
mer
patient
clear
viraemia
day
administr
lopinavirritonavir
ribavirin
suggest
antivir
administr
consid
soon
possibl
base
limit
clinic
evid
earlier
administr
ifn
ribavirin
result
trend
toward
improv
surviv
similarli
sar
therapeut
benefit
observ
ribavirin
given
earlier
day
onset
corticosteroid
ribavirin
monotherapi
mycophenol
acid
like
caus
harm
benefit
corticosteroid
caus
local
system
immunosuppress
administr
associ
higher
plasma
viral
load
slower
viral
clearanc
higher
mortal
sar
furthermor
shown
improv
longerterm
outcom
ribavirin
consid
use
monotherapi
due
poor
side
effect
profil
high
dosag
requir
inhibit
shown
effect
mer
sar
clinic
evid
ribavirin
deem
clinic
data
efficaci
mycophenol
acid
sar
mer
howev
led
sever
andor
fatal
diseas
higher
mean
viral
load
anim
anim
human
transmiss
mer
cov
continu
middl
east
like
infect
individu
continu
export
ill
countri
minim
experi
deal
understand
valu
risk
mani
treatment
option
need
urgent
select
therapeut
regimen
especi
necessarili
stress
public
period
host
countri
institut
medic
team
need
make
decis
base
bodi
avail
inform
give
anyth
clear
direct
treatment
need
appli
adher
research
treatment
protocol
systemat
data
collect
meanwhil
clinic
research
simpli
must
improv
abil
undertak
multicentr
multin
rct
outbreak
set
particularli
emerg
pathogen
none
declar
